EGFR 单抗联合化疗治疗245例晚期头颈鳞癌疗效分析

doi:10.19438/j.cjoms.2019.02.006

中国口腔颌面外科杂志 ›› 2019, Vol. 17 ›› Issue (2): 129-133.doi: 10.19438/j.cjoms.2019.02.006

EGFR 单抗联合化疗治疗245例晚期头颈鳞癌疗效分析

王红¹, 吴云腾², 马旭辉², 郭伟^2,*, 任国欣^1,2,*

1.潍坊医学院口腔医学院,山东潍坊 261000;
2.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,上海 200011

收稿日期:2018-10-26 修回日期:2018-12-12 出版日期:2019-03-20 发布日期:2019-04-12
通讯作者: 郭伟,E-mail：guoweicn@yahoo.com;任国欣,E-mail：renguoxincn@sina.com。^*共同通信作者
作者简介:王红（1991-）,女,硕士研究生,E-mail：13853659313@163.com
基金资助:
上海市科学技术委员会科研资助项目（10410711200,08140902100,11495802000,14DZ1941400）

Efficacy of EGFR monoclonal antibody combined with chemotherapy in treatment of 245 patients with advanced head and neck squamous cell carcinoma

WANG Hong¹, WU Yun-teng², MA Xu-hui², GUO Wei², REN Guo-xin^1,2

1.School of Stomatology, Weifang Medical University.Weifang 261000, Shangdong Province;
2.Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011, China

Received:2018-10-26 Revised:2018-12-12 Online:2019-03-20 Published:2019-04-12

摘要/Abstract

摘要： 目的:评价表皮生长因子受体（EGFR）单抗（泰欣生）治疗晚期头颈部鳞癌的有效性和安全性。方法:选取上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科2008年5月—2017年12月收治的245例晚期（Ⅲ-Ⅳ期）头颈鳞癌患者作为研究对象,分为原发组与复发组,其中原发组152例,复发组93例。原发组和复发组治疗方案均为以铂类为主的化疗联合EGFR单抗100~200 mg/次静滴,分析2组患者的用药安全性和有效性。采用SPSS 17.0软件包对数据进行统计学分析。结果:治疗后,原发组42例口咽癌患者总有效率为81.0%,110例口腔癌患者总有效率为45.4%;复发组9例口咽癌患者总有效率为44.4%,84例口腔癌患者总有效率为27.4%。原发组中位生存期为57个月,复发组中位生存期为8个月;治疗5年后,原发组总生存率为47.7%,复发组总生存率为8.0%。皮疹为EGFR单抗主要不良反应,但发生率仅为1.63%。结论:EGFR单抗联合以铂类为主的化疗对晚期头颈部鳞癌比单纯化疗有更高的有效率和生存率,且止痛效果显著,为手术等后续治疗创造了更好的条件,并可有效改善患者的生活质量,未增加严重化疗不良反应,安全性良好,具有很高的临床推广应用价值。

关键词: EGFR单抗, 头颈部, 鳞癌, 晚期

Abstract: PURPOSE: To study the efficacy and safety of epidermal growth factor receptor(EGFR) monoclonal antibody in the treatment of advanced head and neck squamous cell carcinoma. METHODS: Two hundred and forty-five patients with advanced (stage III-IV) head and neck squamous cell carcinoma were selected from May 2008 to December 2017. They were divided into primary group (n=152) and relapse group (n=93). Both groups received platinum-based chemotherapy combined with EGFR monoclonal antibody 100-200 mg per intravenous drip. The safety and efficacy of the treatment were analyzed. SPSS 17.0 software package was used for statistical analysis. RESULTS: After treatment, the total effective rate was 81.0% in 42 patients with primary oropharyngeal cancer and 45.4% in 110 patients with primary oral cancer, 44.4% in 9 patients with recurrent oropharyngeal cancer and 27.4% in 84 patients with recurrent oral cancer. The median survival time was 57 months in the primary group and 8 months in the relapse group. After five years of treatment, the overall survival rate was 47.7% in the primary group and 8.0% in the relapse group. Skin rash was the main side effect of EGFR mAb, but the incidence was only 1.63%. CONCLUSIONS: EGFR monoclonal antibody combined with platinum-based chemotherapy for advanced head and neck squamous cell carcinoma has a higher effective rate and survival rate than chemotherapy alone, and the analgesic effect is remarkable, which creates a better treatment opportunity for subsequent treatment such as surgery, and can effectively improve the quality of life of patients, and does not increase serious adverse reactions of chemotherapy.

Key words: EGFR monoclonal antibody, Head and neck, Squamous cell carcinoma, Advanced stage

中图分类号:

R739.8

王红, 吴云腾, 马旭辉, 郭伟, 任国欣. EGFR 单抗联合化疗治疗245例晚期头颈鳞癌疗效分析[J]. 中国口腔颌面外科杂志, 2019, 17(2): 129-133.

WANG Hong, WU Yun-teng, MA Xu-hui, GUO Wei, REN Guo-xin. Efficacy of EGFR monoclonal antibody combined with chemotherapy in treatment of 245 patients with advanced head and neck squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2019, 17(2): 129-133.

参考文献

[1] Stewart BW, Kleihues P.World cancer report [R]. Geneva: International Agency for Research on Cancer, 2003: 506-507.
[2] Mountzios G.Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy[J]. World J Clin Oncol, 2015, 6(1): 7-15.
[3] Spector JG, Sessions DG, Chao KS, et al.Management of stage Ⅱ (T2N0M0) glottic carcinoma by radiotherapy and conservation surgery[J]. Head Neck, 1999, 21(2): 116-123.
[4] Sessions DG, Lenox J, Spector GJ.Supraglottic laryngeal cancer: analysis of treatment results[J]. Laryngoscope, 2010, 115(8): 1402-1410.
[5] Seiwert TY, Cohen EE.State-of-the-art management of locally advanced head and neck cancer[J]. Br J Cancer, 2005, 92(8): 1341-1348.
[6] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[7] Posner MR, Haddad RI, Wirth L, et al.Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach[J]. Semin Oncol, 2004, 31(6):778-785.
[8] Lefebvre JL, Chevalier D, Luboinski B, et al.Larynx preservation in pyriform sinus cancer: preliminary results of a european organization for research and treatment of cancer phase Ⅲ trial[J]. J Natl Cancer Inst, 1996, 88(13): 890-899.
[9] 郭伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 口腔颌面外科杂志, 2012, 22(2): 77-81.
[10] Busch CJ, Tribius S, Schafhausen P, et al.The current role of systemic chemotherapy in the primary treatment of head and neck cancer[J]. Cancer Treat Rev, 2015, 41(3): 217-221.
[11] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[12] Mathers CD, Shibuya K, Boschi-Pinto C et al. Global and regional estimates of cancer mortality and incidence by site : I. Application of regional cancer survival model to estimate cancer mortality distribution by site[J]. BMC Cancer, 2002, 2: 36.
[13] Parkin DM, Bray F, Ferlay J, et al.Global cancer statistics, 2002[J]. CA A Cancer J Clin, 2005, 55(2): 74-108.
[14] Lamont EB, Vokes EE.Chemotherapy in the management of squamous-cell carcinoma of the head and neck[J]. Lancet Oncol, 2001, 2(5): 261-269.
[15] Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5): 343-349.
[16] Cohen EE.Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2006, 24(17): 2659-2665.
[17] Kameswaran M, Samuel G, Dev Sarma H, et al.¹³¹I-Nimotuzumab-A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR[J]. Appl Radiat Isot, 2015, 102: 98-102.
[18] Vermorken JB, Specenier P.Optimal treatment for recurrent/metastatic head and neck cancer[J]. Ann Oncol, 2010, 21(Suppl 7): 252-261.
[19] Bonner JA, Harari PM, Giralt J, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6): 567-578.
[20] Vermorken JB, Mesia R, Rivera F, et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11): 1116-1127.
[21] Vermorken JB, Trigo J, Hitt R, et al.Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J]. J Clin Oncol, 2007, 25(16): 2171-2177.
[22] Sundvall M, Karrila A, Nordberg J, et al.EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma[J]. Expert Opin Emerg Drugs, 2010, 15(2): 185-201.
[23] Basavaraj C, Sierra P, Shivu J, et al.Nimotuzumab with chemoradiation confers a survival advantage in treatment-na?ve head and neck tumors over expressing EGFR[J]. Cancer Biol Ther, 2010, 10(7): 673-681.
[24] Xu S, Ramos-Suzarte M, Bai X, et al.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience[J]. Oncotarget, 2016, 7(22): 33391-33407.
[25] Ledón N, Casacó A, Casanova E, et al.Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models[J]. Placenta, 2011, 32(7): 531-534.
[26] Rojo F, Gracias E, Villena N, et al.Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study[J]. Clin Cancer Res, 2010, 16(8): 2474-2482.

EGFR 单抗联合化疗治疗245例晚期头颈鳞癌疗效分析

Efficacy of EGFR monoclonal antibody combined with chemotherapy in treatment of 245 patients with advanced head and neck squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	赵慧, 舒欣, 张帆, 任伟伟, 刘姣, 朱珠. 基于生物信息学和体外实验筛选头颈鳞癌生物标志物[J]. 中国口腔颌面外科杂志, 2024, 22(4): 329-338.
[3]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[4]	郭逸飞, 张永红, 任振虎. 头颈部肉瘤的诊断与治疗现状[J]. 中国口腔颌面外科杂志, 2024, 22(4): 404-408.
[5]	张芳, 寿卫东, 李妍. 医护协同下聚多卡醇泡沫硬化剂治疗头颈部静脉畸形疗效评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 274-278.
[6]	王延安, 秦中平, 郑家伟, 李春洁, 刘少华, 杨耀武, 陈刚, 陈伟良, 刘学键, 杜仲, 张雷, 王业飞, 王德明, 苏立新, 谢峰, 董长宪, 郭磊, 李凯, 顾松, 何悦, 张志愿. 头颈部血管瘤及脉管畸形手术治疗专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(2): 105-117.
[7]	李晨曦, 丁艺, 刘慧, 龚忠诚, 张维娜, 赵化荣. 从循证医学角度探讨妊娠期头颈部癌症的治疗策略[J]. 中国口腔颌面外科杂志, 2024, 22(2): 118-127.
[8]	陈寅瑜, 陈霖, 徐凤, 邹子川, 葛良玉, 孟箭. 过继性T细胞疗法在头颈部鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(2): 192-197.
[9]	李华盛, 周迪, 韩楠男, 严明, 阮敏. 石蒜碱通过降解SCAP蛋白抑制口腔鳞癌细胞增殖与侵袭的实验研究[J]. 中国口腔颌面外科杂志, 2024, 22(1): 29-35.
[10]	刘恒, 李永頔, 尹鑫海, 段晓峰. 铁蛋白重链1在头颈鳞癌中的表达及对口腔鳞癌增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2023, 21(6): 529-537.
[11]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[12]	朱方兴, 周知航, 琚梧桐, 谈亦然, 刘莹, 钟来平, 赵铜超. 基于基线期dNLR水平对局部晚期口腔鳞癌患者生存的预后预测—10年临床回顾[J]. 中国口腔颌面外科杂志, 2023, 21(6): 566-571.
[13]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[14]	李晨曦, 龚忠诚, 赵化荣, 丁明超, 刘慧. 肿瘤治疗电场在头颈部癌症中的应用前景[J]. 中国口腔颌面外科杂志, 2023, 21(5): 425-431.
[15]	翟培淞, 童桐, 刘纯, 马海龙, 张建军. 线粒体拓扑异构酶Ⅰ在头颈鳞癌中的表达及意义[J]. 中国口腔颌面外科杂志, 2023, 21(5): 439-445.